"Neuromuscular Diseases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.
| Descriptor ID |
D009468
|
| MeSH Number(s) |
C10.668
|
| Concept/Terms |
Foley-Denny-Brown Syndrome- Foley-Denny-Brown Syndrome
- Foley Denny Brown Syndrome
- Syndrome, Foley-Denny-Brown
- Fasciculation-Cramp Syndrome, Benign
- Benign Fasciculation-Cramp Syndrome
- Benign Fasciculation-Cramp Syndromes
- Fasciculation Cramp Syndrome, Benign
- Fasciculation-Cramp Syndromes, Benign
- Cramp-Fasciculation Syndrome
- Cramp Fasciculation Syndrome
- Cramp-Fasciculation Syndromes
- Syndrome, Cramp-Fasciculation
- Syndromes, Cramp-Fasciculation
Oppenheim Disease- Oppenheim Disease
- Oppenheim's Disease
- Oppenheims Disease
- Amyotonia Congenita
|
Below are MeSH descriptors whose meaning is more general than "Neuromuscular Diseases".
Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Diseases".
This graph shows the total number of publications written about "Neuromuscular Diseases" by people in this website by year, and whether "Neuromuscular Diseases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuromuscular Diseases" by people in Profiles.
-
Mhandire DZ, Burns DP, Roger AL, O'Halloran KD, ElMallah MK. Breathing in Duchenne muscular dystrophy: translation to therapy. J Physiol. 2022 08; 600(15):3465-3482.
-
Leone P, Tolomeo M, Piancone E, Puzzovio PG, De Giorgi C, Indiveri C, Di Schiavi E, Barile M. Mimicking human riboflavin responsive neuromuscular disorders by silencing flad-1 gene in C. elegans: Alteration of vitamin transport and cholinergic transmission. IUBMB Life. 2022 07; 74(7):672-683.
-
McGarvey L, Rubin BK, Ebihara S, Hegland K, Rivet A, Irwin RS, Bolser DC, Chang AB, Gibson PG, Mazzone SB. Global Physiology and Pathophysiology of?Cough: Part 2. Demographic and Clinical Considerations: CHEST Expert Panel Report. Chest. 2021 10; 160(4):1413-1423.
-
Tolomeo M, Nisco A, Leone P, Barile M. Development of Novel Experimental Models to Study Flavoproteome Alterations in Human Neuromuscular Diseases: The Effect of Rf Therapy. Int J Mol Sci. 2020 Jul 26; 21(15).
-
Baima JA, Silver JK, Most M. Neuromuscular dysfunction in the cancer patient: Evaluation and treatment. Muscle Nerve. 2018 09; 58(3):335-343.
-
ElMallah M, Bailey E, Trivedi M, Kremer T, Rhein LM. Pediatric Obstructive Sleep Apnea in High-Risk Populations: Clinical Implications. Pediatr Ann. 2017 09 01; 46(9):e336-e339.
-
Shenoy AM. Registry Participation in Neuromuscular Disease. Continuum (Minneap Minn). 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):2012-2014.
-
Salameh JS, Deeb W, Burawski L, Wright S, Souayah N. Safety and Efficacy of Subcutaneous Immunoglobulin in the Treatment of Neuromuscular Disorders. J Clin Neuromuscul Dis. 2016 Mar; 17(3):110-9.
-
Fahey M. Floppy baby. J Paediatr Child Health. 2015 Apr; 51(4):355-6.
-
Cheever TR, Berkley D, Braun S, Brown RH, Byrne BJ, Chamberlain JS, Cwik V, Duan D, Federoff HJ, High KA, Kaspar BK, Klinger KW, Larkindale J, Lincecum J, Mavilio F, McDonald CL, McLaughlin J, Weiss McLeod B, Mendell JR, Nuckolls G, Stedman HH, Tagle DA, Vandenberghe LH, Wang H, Wernett PJ, Wilson JM, Porter JD, Gubitz AK. Perspectives on best practices for gene therapy programs. Hum Gene Ther. 2015 Mar; 26(3):127-33.